In clinical studies, synDNA vaccines delivered with EP have proven highly effective in small and large animal models of infectious disease and cancer, and have demonstrated the ability to drive a tissue infiltrating population of antigen-specific CD8 T cells [47]. Here, CD8A is linked to cancer.